216 results on '"Jung, Gundram"'
Search Results
2. CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients
3. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
4. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
5. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer
6. Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity
7. An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
8. Cloned Transgenic Farm Animals Produce a Bispecific Antibody for T Cell-Mediated Tumor Cell Killing
9. CD105 (Endoglin) as negative prognostic factor in AML
10. The challenges of translation
11. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
12. Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
13. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
14. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
15. IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases
16. Abstract 2859: Platelet-derived TGFβ undermines treatment efficacy of t cell recruiting bispecific antibodies
17. Abstract CT141: CC-1, a bispecific PSMAxCD3 antibody for treatment of prostate carcinoma: Results of the ongoing phase I dose escalation trial
18. Abstract 2078: CLN-049 is a bispecific T cell engaging IgG-like antibody targeting FLT3 on AML cells
19. Abstract 2860: A CD135 immunocytokine with target cell-restricted IL-15 activity for treatment of AML
20. Abstract 2865: CC-3, an IgG-based B7-H3xCD3 bispecific antibody for targeting of gastrointestinal cancers
21. Abstract 2886: Antigen internalization and its prevention during treatment with bispecific antibodies
22. Abstract 2864: A CLEC12A immunocytokine with target cell-restricted IL-15 activity shows a favorable toxicity profile and high potency in AML
23. Abstract 2863: Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies
24. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
25. Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
26. CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
27. Activation of Human Peripheral Blood Mononuclear Cells by Anti-T3: Killing of Tumor Target Cells Coated with Anti-Target--Anti-T3 Conjugates
28. Lymphokine-Activated Killer Cells Targeted by Monoclonal Antibodies to the Disialogangliosides GD2 and GD3 Specifically Lyse Human Tumor Cells of Neuroectodermal Origin
29. Disialoganglioside GD3 on Human Melanoma Serves as a Relevant Target Antigen for Monoclonal Antibody-Mediated Tumor Cytolysis
30. The Cytolytic Protein of Human Lymphocytes Related to the Ninth Component (C9) of Human Complement: Isolation from Anti-CD3-Activated Peripheral Blood Mononuclear Cells
31. Induction of Synthesis of the Cytolytic C9 (Ninth Component of Complement)-Related Protein in Human Peripheral Mononuclear Cells by Monoclonal Antibody OKT3 or Interleukin 2: Correlation with Cytotoxicity and Lymphocyte Phenotype
32. Induction of Cytotoxicity in Resting Human T Lymphocytes Bound to Tumor Cells by Antibody Heteroconjugates
33. Capture of endothelial progenitor cells by a bispecific protein/monoclonal antibody molecule induces reendothelialization of vascular lesions
34. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
35. An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
36. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells
37. Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats
38. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
39. An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
40. First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease
41. Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
42. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
43. Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
44. An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer
45. Herpes virus entry mediator synergizes with Toll-like receptor mediated neutrophil inflammatory responses
46. Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules
47. Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease
48. Immunocytokines with Target Cell-Restricted IL-15 Activity for Induction of NK Cell Reactivity Against Acute Myeloid Leukemia (AML)
49. Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody
50. A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.